In this episode, Martin discusses two short positions that he says have reached their objectives and explains why he is taking profits. He also shares signals generated by his quantitative investment model, highlighting two stocks that it currently identifies as long opportunities and discussing the factors behind those selections and how they fit into his broader investment approach.

In this episode, Martin discusses his view that advances in AI could fundamentally reshape the software-as-a-service (SaaS) industry over the coming years. He explains the reasoning behind this thesis, examines the potential impact of AI agents on software businesses, and shares his perspectives on HubSpot, CAPR, and Nvidia, discussing how these companies may be affected by changing technology trends and evolving market conditions.

In this episode, Martin challenges a market narrative that he believes investors should view with skepticism before explaining his reasoning. He also analyzes Analog Devices (ADI), discusses his bullish outlook on Google, and shares his views on Oracle and Palantir, examining their valuations, competitive positions, and the factors influencing his investment outlook for each company.

In this episode, Martin shares the long positions currently in his portfolio and explains the investment thesis behind several of his holdings. He also discusses why he believes Samsung has significant upside potential, and comments on a LinkedIn post by the Sellas Life Sciences CEO, examining how it relates to the company and investor sentiment.

In this episode, Martin discusses the market activity surrounding CAPR and shares his perspective on legal action related to the company. He also analyzes Moderna, Adobe, and CRISPR Therapeutics (CRSP), examining their valuations, competitive positions, and future prospects while explaining the factors influencing his outlook on each stock.

In this episode, Martin discusses what he believes Samsung’s recent developments reveal about broader challenges facing the semiconductor industry. He also examines Adobe’s valuation following its recent decline, shares his views on whether the stock has become oversold, and reviews Acadia Pharmaceuticals (ACAD) and Denali Therapeutics, evaluating their businesses, pipelines, and investment outlooks.

In this episode, Martin discusses investment opportunities that he believes the broader market may not yet fully appreciate. He shares his views on Nvidia, Apple, and PayPal, examining their valuations, competitive positions, and future prospects. He also offers his perspective on managing portfolio drawdowns, discussing strategies for handling losses, maintaining discipline, and making investment decisions during periods of market volatility.

In this episode, Martin examines the argument that advances in artificial intelligence could significantly disrupt or replace traditional software companies. He discusses the assumptions behind this view, evaluates which types of businesses may be more or less affected by AI, and shares his perspective on how the technology could reshape the software industry and investment landscape over time.

In this episode, Martin discusses several investment ideas that he believes present attractive opportunities, including Vaxcyte, Vera Therapeutics, and Spruce Biosciences. He also analyzes Tvardi Therapeutics, explaining his perspective on the company's prospects, and outlines his reasoning for taking a short position in OKLO while comparing the risks and potential rewards across these investments.

In this episode, Martin discusses the skills, habits, and mindset he believes are essential for becoming a successful investor. Drawing on his own experience, he shares his perspective on research, decision-making, risk management, and developing an edge in the market, while explaining how investors can improve their analytical process over time.